Last reviewed · How we verify
clopidogrel plus aspirin
Clopidogrel is an antiplatelet medication that inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 receptor, while aspirin is an antiplatelet medication that inhibits platelet aggregation by irreversibly acetylating the cyclooxygenase-1 enzyme.
Clopidogrel is an antiplatelet medication that inhibits platelet activation and aggregation by irreversibly binding to the P2Y12 receptor, while aspirin is an antiplatelet medication that inhibits platelet aggregation by irreversibly acetylating the cyclooxygenase-1 enzyme. Used for Atrial fibrillation for stroke prevention, Acute coronary syndrome.
At a glance
| Generic name | clopidogrel plus aspirin |
|---|---|
| Also known as | Plavix plus ASA, Standard Care |
| Sponsor | Catholic University of the Sacred Heart |
| Drug class | antiplatelet |
| Target | P2Y12 receptor |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Clopidogrel works by blocking the P2Y12 receptor on platelets, which is responsible for platelet activation and aggregation. Aspirin works by inhibiting the production of thromboxane A2, a substance that promotes platelet aggregation. The combination of clopidogrel and aspirin is used to prevent blood clots and reduce the risk of heart attack and stroke.
Approved indications
- Atrial fibrillation for stroke prevention
- Acute coronary syndrome
Common side effects
- Gastrointestinal bleeding
- Thrombocytopenia
- Neutropenia
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |